年终盘点 | 以康宁杰瑞-B(9966.HK)为例，洞见差异化创新的医药硬科技

Core Viewpoint - In 2025, under the new "dual circulation" development pattern, China's capital market is undergoing a profound transformation, with the innovative drug sector emerging as a standout performer, marked by significant capital investment and a shift towards "hard technology" [1][3]. Industry Overview - The innovative drug sector has entered a clear structural bull market in 2025, driven by valuation recovery, policy support, and the trend of business development (BD) overseas, leading to a systematic reconstruction of the valuation framework [3]. - The investment logic in innovative drugs has shifted from a narrative focused on "stories and pipelines" to a deeper pricing based on "commercialization capability" and "sustained innovation momentum" [3]. - The competition in the future will focus on "platform-based innovation capability" rather than betting on single-target "probability games" [4]. Company Performance - 康宁杰瑞 (Cangning Jierei) achieved a remarkable stock price increase of 220.57% in 2025, becoming a leader among mid-to-large unprofitable biotech companies, and was awarded the "Annual Innovation Award" by 格隆汇 (Gelonghui) for its innovative model [1][5]. - The company successfully transitioned from early product development to focusing on the dual antibody/ADC golden track, marking a fundamental shift from "single product-driven" to "technology platform-driven" [7]. - Financially, 康宁杰瑞 reported a revenue of 319 million yuan in the first half of 2025, an 84% year-on-year increase, and a net profit of 21.58 million yuan, maintaining positive profitability [9]. Future Outlook - In 2026, 康宁杰瑞 is expected to enter a critical period for innovation results and value validation, with several milestone events and clinical data readouts acting as clear catalysts [12]. - Key products include KN026, JSKN003, and JSKN016, with anticipated regulatory approvals and clinical data expected to further solidify the company's position in the market [12][13]. - The capital market's recognition of 康宁杰瑞 is deepening, with multiple institutions raising ratings and target prices, indicating a clear long-term growth potential [13]. Conclusion - 康宁杰瑞's journey in 2025 reflects a broader transformation in the Chinese innovative drug landscape, emphasizing the importance of systematic platform capabilities over single blockbuster products [16][17]. - As the industry transitions from beta-driven benefits to alpha-driven differentiation, companies like 康宁杰瑞, with independent platforms and clear clinical strategies, are poised to become market leaders and define the next generation of treatment standards [16][18].